🚀 VC round data is live in beta, check it out!
Oncoclínicas Valuation Multiples
Discover revenue and EBITDA valuation multiples for Oncoclínicas and similar public comparables like M1 Kliniken, Medica Sur, Mater Dei, Pihlajalinna and more.
Oncoclínicas Overview
About Oncoclínicas
Oncoclinicas Do Brasil Servicos Medicos SA is engaged in the management and administration of oncological services. It has specialists in the areas of oncology, radiotherapy, hematology, and bone marrow transplantation, complementary care. The Group operates solely in the healthcare services segment, with an emphasis on oncology.
Founded
2010
HQ
Employees
10.8K
Website
Sectors
Financials (LTM)
EV
$1B
Oncoclínicas Financials
Oncoclínicas reported last 12-month revenue of $1B and negative EBITDA of ($95M).
In the same LTM period, Oncoclínicas generated $389M in gross profit, ($95M) in EBITDA losses, and had net loss of ($307M).
Revenue (LTM)
Oncoclínicas P&L
In the most recent fiscal year, Oncoclínicas reported revenue of $1B and EBITDA of ($220M).
Oncoclínicas expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $1B | XXX | $1B | XXX | XXX | XXX |
| Gross Profit | $389M | XXX | $357M | XXX | XXX | XXX |
| Gross Margin | 33% | XXX | 30% | XXX | XXX | XXX |
| EBITDA | ($95M) | XXX | ($220M) | XXX | XXX | XXX |
| EBITDA Margin | (8%) | XXX | (19%) | XXX | XXX | XXX |
| EBIT Margin | (10%) | XXX | (20%) | XXX | XXX | XXX |
| Net Profit | ($307M) | XXX | ($449M) | XXX | XXX | XXX |
| Net Margin | (26%) | XXX | (38%) | XXX | XXX | XXX |
| Net Debt | — | — | $555M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Oncoclínicas Stock Performance
Oncoclínicas has current market cap of $353M, and enterprise value of $1B.
Market Cap Evolution
Oncoclínicas' stock price is $0.32.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $353M | 14.9% | XXX | XXX | XXX | $-0.40 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialOncoclínicas Valuation Multiples
Oncoclínicas trades at 0.8x EV/Revenue multiple, and (10.7x) EV/EBITDA.
EV / Revenue (LTM)
Oncoclínicas Financial Valuation Multiples
As of April 22, 2026, Oncoclínicas has market cap of $353M and EV of $1B.
Equity research analysts estimate Oncoclínicas' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Oncoclínicas has a P/E ratio of (1.2x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $353M | XXX | $353M | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/Revenue | 0.8x | XXX | 0.9x | XXX | XXX | XXX |
| EV/EBITDA | (10.7x) | XXX | (4.6x) | XXX | XXX | XXX |
| EV/EBIT | (8.2x) | XXX | (4.3x) | XXX | XXX | XXX |
| EV/Gross Profit | 2.6x | XXX | 2.8x | XXX | XXX | XXX |
| P/E | (1.2x) | XXX | (0.8x) | XXX | XXX | XXX |
| EV/FCF | 5.6x | XXX | 6.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Oncoclínicas Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Oncoclínicas Margins & Growth Rates
Oncoclínicas' revenue in the last 12 month grew by 5%.
Oncoclínicas' revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Oncoclínicas' rule of 40 is 23% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Oncoclínicas' rule of X is 34% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Oncoclínicas Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 5% | XXX | 5% | XXX | XXX | XXX |
| EBITDA Margin | (8%) | XXX | (19%) | XXX | XXX | XXX |
| EBITDA Growth | (310%) | XXX | (187%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 23% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 34% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 23% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 72% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Oncoclínicas Public Comps
See public comps and valuation multiples for other Hospitals & Clinics comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Oncoclínicas | XXX | XXX | XXX | XXX | XXX | XXX |
| M1 Kliniken | XXX | XXX | XXX | XXX | XXX | XXX |
| Medica Sur | XXX | XXX | XXX | XXX | XXX | XXX |
| Mater Dei | XXX | XXX | XXX | XXX | XXX | XXX |
| Pihlajalinna | XXX | XXX | XXX | XXX | XXX | XXX |
| Auna | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Oncoclínicas M&A Activity
Oncoclínicas acquired XXX companies to date.
Last acquisition by Oncoclínicas was on XXXXXXXX, XXXXX. Oncoclínicas acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Oncoclínicas
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialOncoclínicas Investment Activity
Oncoclínicas invested in XXX companies to date.
Oncoclínicas made its latest investment on XXXXXXXX, XXXXX. Oncoclínicas invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Oncoclínicas
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Oncoclínicas
| When was Oncoclínicas founded? | Oncoclínicas was founded in 2010. |
| Where is Oncoclínicas headquartered? | Oncoclínicas is headquartered in Brazil. |
| How many employees does Oncoclínicas have? | As of today, Oncoclínicas has over 10K employees. |
| Who is the CEO of Oncoclínicas? | Oncoclínicas' CEO is Bruno Lemos Ferrari. |
| Is Oncoclínicas publicly listed? | Yes, Oncoclínicas is a public company listed on B3. |
| What is the stock symbol of Oncoclínicas? | Oncoclínicas trades under ONCO3 ticker. |
| When did Oncoclínicas go public? | Oncoclínicas went public in 2021. |
| Who are competitors of Oncoclínicas? | Oncoclínicas main competitors are M1 Kliniken, Medica Sur, Mater Dei, Pihlajalinna. |
| What is the current market cap of Oncoclínicas? | Oncoclínicas' current market cap is $353M. |
| What is the current revenue of Oncoclínicas? | Oncoclínicas' last 12 months revenue is $1B. |
| What is the current revenue growth of Oncoclínicas? | Oncoclínicas revenue growth (NTM/LTM) is 5%. |
| What is the current EV/Revenue multiple of Oncoclínicas? | Current revenue multiple of Oncoclínicas is 0.8x. |
| Is Oncoclínicas profitable? | No, Oncoclínicas is not profitable. |
| What is the current EBITDA of Oncoclínicas? | Oncoclínicas has negative EBITDA and is not profitable. |
| What is Oncoclínicas' EBITDA margin? | Oncoclínicas' last 12 months EBITDA margin is (8%). |
| What is the current EV/EBITDA multiple of Oncoclínicas? | Current EBITDA multiple of Oncoclínicas is (10.7x). |
| What is the current FCF of Oncoclínicas? | Oncoclínicas' last 12 months FCF is $180M. |
| What is Oncoclínicas' FCF margin? | Oncoclínicas' last 12 months FCF margin is 15%. |
| What is the current EV/FCF multiple of Oncoclínicas? | Current FCF multiple of Oncoclínicas is 5.6x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.